Searched for
BIOCON YESINTEK
Biocon gets Health Canada nod for Yesintek autoinjector penBiocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for pso...- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
- Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IVBiocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest a...
- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...
- Biocon Biologics secures multiple market access agreements in US for YesintekBiocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 million lives. Mult...
- Biocon shares in focus after successful results of Yesintek in Phase 3Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...
- Biocon shares in focus after subsidiary launches biosimilar alternative to Stelara in the USBiocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering ...
- Stocks in news: ONGC, NTPC, SBI Life, Manappuram Finance, BioconNTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore in the state.
- Stocks in news: Vedanta, Dixon Tech, Bharat Forge, ONGC, RILDixon Technologies and Chinese smartphone maker Vivo are entering into a joint venture that will manufacture smartphones for the smartphone...
- Stocks in news: Greaves Cotton, Biocon, Tata Motors, Hyundai, CiplaMarkets advanced nearly 1% last week, recording a two-week rally. Focus today includes Greaves Cotton's IPO plan for its subsidiary, Biocon...
- Biocon Biologics gets US nod to launch Stelara biosimilarBiocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions...
Load More
